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Abstract We recently provided evidence for a mitochon-
drial dysfunction in P301L tau transgenic mice, a strain
modeling the tau pathology of Alzheimer’s disease (AD)
and frontotemporal dementia (FTD). In addition to tau
aggregates, the AD brain is further characterized by Aβ
peptide-containing plaques. When we addressed the role of
Aβ, this indicated a synergistic action of tau and Aβ
pathology on the mitochondria. In the present study, we
compared the toxicity of different Aβ42 conformations in
light of recent studies suggesting that oligomeric rather than
fibrillar Aβ might be the actual toxic species. Interestingly,
both oligomeric and fibrillar, but not disaggregated (mainly
monomeric) Aβ42 caused a decreased mitochondrial
membrane potential in cortical brain cells obtained from
FTD P301L tau transgenic mice. This was not observed
with cerebellar preparations indicating selective vulnerabil-
ity of cortical neurons. Furthermore, we found reductions in
state 3 respiration, the respiratory control ratio, and
uncoupled respiration when incubating P301L tau mito-
chondria either with oligomeric or fibrillar preparations of
Aβ42. Finally, we found that aging specifically increased
the sensitivity of mitochondria to oligomeric Aβ42 damage
indicating that oligomeric and fibrillar Aβ42 are both toxic,
but exert different degrees of toxicity.
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Introduction
β-Amyloid (Aβ)-containing plaques and tau-containing
neurofibrillary tangles (NFTs) are hallmarks for brain lesions
in both familial and sporadic cases of Alzheimer’s disease
(AD); however, how these lesions and their proteinaceous
components impair cellular functions and ultimately lead to
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neuronal cell loss is only partly understood [1–3]. Attempts
to gain insight into pathogenic mechanisms, and eventually,
to develop therapeutic strategies have been greatly assisted
by experimental animal models that express mutant forms
of AD-associated genes [4, 5].
In AD, pathogenic mutations have been identified in
both the gene encoding the precursor of the Aβ peptide,
APP, itself and in the PSEN genes which encode part of the
APP–protease complex. No mutations have been identified
in the MAPT gene encoding the microtubule-associated
protein tau [5]. Although AD is the most prevalent form of
dementia at high age, NFTs are, in the absence of Aβ
plaques, also abundant in additional neurodegenerative
diseases, including frontotemporal dementia (FTD). In
familial cases of FTD (FTD with Parkinsonism linked to
chromosome 17 (FTDP-17)), exonic and intronic mutations
have been identified in the MAPT gene which lead to the
formation of tau aggregates in the brain [6]. Gallyas silver
impregnation techniques are frequently employed to visualize
NFTs in both AD and FTD brains [7].
The P301L tau mutation was among the first to be
identified in FTDP-17 [8]. It was expressed by us in
neurons of transgenic mice [9]. P301L tau transgenic mice
develop NFTs that contain aggregated forms of hyper-
phosphorylated tau and show age-related memory impair-
ment [10, 11]. Whereas transgenic mice expressing human
APP with mutations found in familial cases of AD develop
Aβ plaques, they fail to form NFTs. On the other hand, the
P301L transgenic pR5 mice model aspects of the tau
pathology of AD and FTD, but lacks plaque pathology. Both
pathologies have been successfully combined either by
crossing the respective transgenic strains or by establishing
so-called triple transgenic mice [12] (reviewed in [13]). We
addressed the pathogenic relationship of Aβ plaques and
NFTs by an alternative approach that is by injecting fibrillar
preparations of Aβ42 stereotaxically into the somatosenso-
ry cortex and the hippocampus of P301L and wild-type
human tau transgenic mice and non-transgenic littermate
controls. As shown previously, this caused a fivefold
increase of NFTs in the amygdala of P301L transgenic,
but not wild-type tau transgenic or control mice [14]. NFT
formation was correlated with the phosphorylation of the
pS422 and AT100 epitopes of tau [9, 15]. These findings
could be confirmed by us in vitro, using neuronally
differentiated SH-SY5Y neuroblastoma cells [16].
Subsequently, in addition to transcriptomic approaches [17,
18], we performed a proteomic and functional analysis of
P301L tau transgenic mice which revealed a mitochondrial
dysfunction together with a reduced electron transport chain
complex I activity [19]. We also provided first evidence for
an increased vulnerability of P301L tau mitochondria
towards fibrillar Aβ insult, suggesting a synergistic action
of tau and Aβ pathology on the mitochondria [19–21].
In recent years, attempts have been undertaken to identify
the toxic species of Aβ. The focus of attention has since
shifted from fibrillar to oligomeric species as the large,
insoluble Aβ deposits which form the amyloid plaques in the
limbic and association cortices of AD patients are in
equilibrium with small, diffusible Aβ oligomers that appear
capable of interfering with hippocampal synaptic function
and memory [22]. Thus, in this study, we determined
whether oligomeric Aβ42 would already exert a pro-
nounced toxicity towards P301L tau transgenic mitochon-
dria, compared to disaggregated (mainly monomeric) and
fibrillar Aβ.
Materials and methods
Transgenic mice
The transgenic mice used in the present study express the
human pathogenic mutation P301L of tau together with the
longest human brain tau isoform (htau40) under control of
the neuron-specific mThy1.2 promoter [9]. The htau40
isoform contains exons 2 and 3 as well as four microtubule-
binding repeats (2+3+4R, human tau40). Pronuclear injec-
tions were done into C57Bl/6 × DBA/2 F2 oocytes to
obtain founder animals that were back-crossed with C57Bl/
6 mice to establish transgenic lines as described [23].
P301L tau mice show tau hyperphosphorylation already at
3 months [9]. NFT formation starts at 6 months of age [14].
Consistent with our previous studies [19], the mice were
analyzed at 13–15 and 21–22 months of age. The mice
were maintained in a 12-h dark–light cycle with pelleted
food and water ad libitum. Animals were handled according
to the Swiss guidelines for animal care. The experiments
were conducted in accordance with international standards
on animal welfare as well as being compliant with local
regulations.
Monomer, oligomer, and fibril preparation
The Aβ42 synthetic peptide (H-1368, Bachem, Bubendorf,
Switzerland) was suspended in 100% 1,1,1,3,3,3 hexa-
fluoro-2-propanol (HFIP) at 6 mg/ml and incubated for
complete solubilization under shaking at 37°C for 1.5 h as
described previously [24].
Monomeric preparation [24] To obtain the monomeric
preparation, 30 mg HFIP-treated Aβ42 was resuspended
in 132 μl dimethylsulfoxide (DMSO) at RT for 10 min. A
60 ml buffer (20 mM NaPi, 140 mM NaCl, and 0.1%
Pluronic F68 pH 7.4) was added and the mixture stirred for
1 h at RT. Following a 20 min centrifugation at 3,000×g,
the supernatant was discarded and the pellet resuspended in
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6 ml buffer. Then, 34 ml of H2O was added and the mixture
stirred for 1 h at RT. Following a second centrifugation for
20 min at 3,000×g, the supernatant was stored as 5 ml
aliquots at −80°C.
Oligomeric preparation [24] To obtain the oligomeric
preparation, HFIP was removed by evaporation in a
SpeedVac and Aβ42 resuspended at a concentration of
5 mM in DMSO and sonicated for 20 s as described [16].
The HFIP-pretreated Aβ42 was diluted in phosphate-
buffered saline (20 mM NaH2PO4, 140 mM NaCl,
pH 7.4) to 400 μM and 1/10 volume 2% sodium dodecyl
sulfate (SDS; in H2O) was added (final concentration of
0.2% SDS). An incubation for 6 h at 37°C resulted in the
16/20-kDa Aβ42 globulomer (short form for globular
oligomer) intermediate. The 38/48-kDa Aβ42 globulomer
was generated by a further dilution with three volumes of
H2O and incubation for 18 h at 37°C. This was followed by
centrifugation for 20 min at 3,000×g and concentrating the
supernatant to 1.8 ml by dialysis against 5 mM NaPi,
35 mM NaCl pH 7.4 overnight at 6°C with a 30-kD
centriprep and subsequent centrifugation of the concentrate
for 10 min at 10,000×g. The supernatant was then stored in
100 μl aliquots at −80°C.
Fibrillar preparation adapted from previously described
methods [16, 25] To prepare fibrillar Aβ42, the peptide was
dissolved in Tris-buffered saline pH 7.4 (TBS) at a concen-
tration of 0.5 mM and stored at −20°C. (All aqueous solutions
were prepared with deionized and filtered water (Millipore)).
The stock solution was diluted in TBS to a concentration of
50 μM and incubated at 37°C with gentle agitation for 24 h to
obtain aged, aggregated preparations of Aβ42.
Visualization of Aβ preparations on sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) gels
The samples were analyzed using Tris-glycine 4–20%
gradient SDS-PAGE gels and stained with Coomassie
Brilliant Blue R250 according to [24]. Gels were scanned
with an Epson 4180 scanner.
Structural characterization of Aβ aggregates
For negative staining analysis, 4 μl of the sample was
placed on copper grids covered with formvar and carbon
and counterstained with 2% uranyl acetate, using the
droplet technique [26]. Specimens were examined in a
Zeus 902 transmission electron microscope operated at an
acceleration voltage of 80 kV.
Thioflavine T (ThT) spectra were recorded at room
temperature with a Shimadzu RF-5301PC fluorimeter,
using an excitation wavelength of 482 nm and a cuvette
with 5 mm path length. Samples contained a final
concentration of 20 μM ThT and 5 μM Aβ42 in 5 mM
NaPi/35 mM NaCl, pH 7.4 (globulomers) or TBS, pH 7.4
(fibrils).
Congo Red (CR) absorption spectra were recorded at
room temperature, using an Analytik Jena Specord 210
spectrophotometer. Samples contained a final concentration
of 10 μM CR and 15 μM Aβ42 in 5 mM NaPi/35 mM
NaCl, pH 7.4 (globulomers) or TBS, pH 7.4 (fibrils).
For attenuated total reflection Fourier transform infrared
(ATR-FTIR) spectroscopy, Aβ42 fibrils were concentrated
by centrifugation for 30 min at 500,000×g and 25°C in a
Beckman Optima TLX ultracentrifuge, using a Beckman
TLA-120.2 rotor. Subsequently, the fibril pellet was
resuspended in a small volume of TBS, pH 7.4 by pipetting
and vortexing. ATR-FTIR spectra of 1.9 mM Aβ42
globulomers in 5 mM NaPi/35 mM NaCl, pH 7.4 and
1.1 mM Aβ42 fibrils in TBS, pH 7.4 were recorded as
described [27].
Brain tissue preparation for mitochondrial analysis
Cellular preparations were obtained to determine the
mitochondrial membrane potential (MMP) and mitochondria
and to determine respiration rates as previously described
[19, 25]. For that, mice (six pairs of 13–15-month-old and
six pairs of 21–22-month-old hemizygous P301L tau and
WT control mice) were sacrificed by decapitation and brains
quickly dissected on ice. The cerebellum and one cortical
hemisphere (the other hemisphere was directly used for
preparation of isolated mitochondria for mitochondrial
respiration) were separately minced into 1 ml of medium I
(138 mM NaCl, 5.4 mM KCl, 0.17 mM Na2HPO4, 0.22 mM
K2PO4, 5.5 mM glucose, 58.4 mM sucrose, pH 7.35) with a
scalpel and further dissociated by trituration through a nylon
mesh (pore diameter 1 mm) with a pasteur pipette. The
resulting suspension, which contained both neuronal (about
72%) and glial cells (about 26%), was filtered by gravity
through a fresh nylon mesh with a pore diameter of 102 μm,
and the dissociated cell aggregates were washed twice with
medium II (110 mM NaCl, 5.3 mM KCl, 1.8 mM
CaCl2·H2O, 1 mM MgCl2·6 H2O, 25 mM glucose, 70 mM
sucrose, 20 mM 4-(2-hydroxyethyl)piperazine-1-ethanesul-
fonic acid (HEPES), pH 7.4) by centrifugation (400×g for
3 min at 4°C). One hundred microliters of the suspension
were used for protein determination. After centrifugation,
cells were resuspended in 3 ml DMEM, and then aliquots of
100 μl were distributed per well in a 48-well plate for
measurement of the mitochondrial membrane potential. The
preparations of cerebellar and cortical cells from P301L tau
transgenic mice and WT littermate controls (cross-over
design) were made within 2 h under the same conditions
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and in parallel and maintained at 37°C in a humidified
atmosphere of 5% CO2/95% air. Viability was found to be
>90% using the MTT assay and trypan blue stain exclusion
test. Data are expressed as fluorescence units per milligram
protein.
Determination of the mitochondrial membrane potential
Themembrane potential of the inner mitochondrial membrane
was measured using the rhodamine 123 (Molecular Probes,
Leiden, Netherlands) dye added to the cell culture medium at
a final concentration of 0.4 μM for 15min. Cells were washed
twice with Hank’s balanced salt solution (Sigma, Germany),
and fluorescence was determined with a Victor2 multiplate
reader (Perkin Elmer, Rodgau-Jügesheim, Germany) at 490/
535 nm (Ex/Em). Loading capacity of the dye within the
membrane decreases when the mitochondrial membrane
potential declines after damage, e.g., exposure to Aβ42. For
the secondary insult with Aβ42, cells were incubated for 4 h
with the different types of preparation as described above. For
this purpose, monomeric and oligomeric preparations were
handled with specific care to avoid destabilization of
conformation. Thus, frozen aliquots were quickly thawed
and immediately diluted to the final assay concentration
(maximal incubation time at 37°C for 4 h only within the
nanomolar concentration range ≤100 nM). Since pre-experi-
ments had shown that a maximum effect of fibrillar Aβ42
with regard to a reduction of MMP was reached at a
concentration of 50 nM whereas 100 nM did not further
decrease MMP (data not shown), the latter concentration was
omitted due to limited brain material.
Preparation of isolated mitochondria
Mice were sacrificed by decapitation and one brain
hemisphere was rapidly dissected on ice and washed in
ice-cold buffer (210 mM mannitol, 70 mM sucrose, 10 mM
HEPES, 1 mM ethylenediamine tetraacetic acid (EDTA),
0.45% BSA, 0.5 mM DTT, protease inhibitor cocktail
(Complete tablets, Roche Diagnostics). After removing the
cerebellum and one cortical hemisphere for the determina-
tion of the membrane potential (see above), the second
cortical hemisphere was homogenized in 2 ml buffer with a
glass homogenizer (10 to 15 strokes, 400 rpm) followed by
centrifugation at 1,400×g for 7 min at 4°C, to remove
nuclei and tissue particles. This low speed centrifugation
step was repeated once with the supernatant. Then, the
supernatant fraction was centrifuged at 10,000×g for 5 min
at 4°C to pellet mitochondria. The resulting pellet was
resuspended in 1 ml ice-cold buffer and centrifuged again at
800×g for 3 min at 4°C. Finally, the mitochondria-enriched
supernatant was centrifuged at 10,000×g for 5 min at 4°C to
obtain a mitochondrial fraction. This fraction was resus-
pended in 100 μl of ice-cold buffer and stored at 4°C until
use, followed by determination of protein content.
Mitochondrial respiration
The rate of mitochondrial respiration was monitored at 25°C
using an Oxygraph-2k system (Oroboros, Innsbruck, Austria)
equipped with two chambers and DatLab software. Mito-
chondria (0.5 mg) were added to 2 ml of a buffer containing
65 mM sucrose, 10 mM potassium phosphate, 10 mM Tris–
HCl, 10 mM MgSO4, and 2 mM EDTA (pH 7.0). State 4
respiration was measured after adding 40 μl malate/
glutamate (240 mM/280 mM; assay concentration 4.8/
5.6 mM). Then, 10 μl adenosine diphosphate (ADP;
100 mM; assay concentration 0.5 mM) was added to
measure state 3 respiration. After determining coupled
respiration, 1 μl carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP, 0.1 mM; assay concentration
0.05 nM) was added to the reaction chamber, and respiration
measured in the absence of a proton gradient. To inhibit
complex I activity, a total volume of 3 μl (2+1 μl) rotenone
(0.1 mM; final concentration 0.15 nM) was added. Then,
10 μl succinate (1 M; final concentration 5 mM) was added
and complex II-dependent respiration was measured. Finally,
8 μl KCN (0.5 M; assay concentration 2 mM) was added to
inhibit complex IV activity. P301L tau transgenic and WT
mitochondria were measured in parallel using the same
conditions (cross-over design in the two chamber system).
On a routine basis, the intactness of mitochondria was
confirmed by addition of cytochrome c (10 μM). To test the
effect of Aβ42 on mitochondrial respiration, isolated
mitochondria were exposed to different types of Aβ42
preparations (5 μM) or vehicle on ice. Then, the mitochon-
dria suspension was added into the chamber (final concen-
tration of Aβ42 preparation 100 nM).
Statistical analysis
Data are represented as mean ± SEM. For statistical
comparison, two-way ANOVA followed by post hoc t test
was used. Only p values less than 0.05 were considered
statistically significant.
Results
We previously reported a mitochondrial dysfunction in
P301L tau transgenic mice that is not caused by alterations
in numbers of mitochondria [19]. Furthermore, in aged
P301L tau mice, we had found a significantly reduced state
3 respiration, and thus markedly reduced respiratory control
ratio compared to age-matched WT mice. First evidence
was provided that a secondary insult with Aβ42 caused a
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higher reduction in membrane potential in P301L tau
mitochondria than in WT. Here, we aimed to determine
the relative toxicity of oligomeric compared to fibrillar
Aβ42 with regards to mitochondrial function, by testing
disaggregated (mainly monomeric), oligomeric, and fibril-
lar preparations of Aβ42.
Characterization of Aβ42 species
Monomeric Aβ42 was generated by an initial resuspension
of Aβ42 in 1,1,3,3,3 hexafluoro-2-propanol (HFIP) fol-
lowed by two centrifugation steps. The majority of the
preparation was monomeric with some heterogeneous Aβ
peptides that migrated on SDS-PAGE as trimers and
tetramers (Fig. 1a). This preparation was, within the limits
of detection, free of oligomers (no band at 50 kDa) and
fibrils as confirmed by negative contrast electron micros-
copy (data not shown). Hence, this preparation was termed
‘disaggregated’.
The oligomeric preparation with an apparent molecular
weight of 50 kDa was generated by a series of concentra-
tion, centrifugation, and dialysis steps. Figure 1b shows a
Coomassie Blue staining of an SDS-PAGE gel after the
initial preparation of Aβ42 (10 μl, lane 2), after concen-
tration (0.5 μl, lane 3), after concentration and dialysis
(0.5 μl, lane 4), and the flow through (10 μl, lane 5). After
concentrating the sample (lanes 3 and 4), the preparation
mainly consisted of oligomeric Aβ42, with monomeric
Aβ42 and trimers and tetramers being only a minor
contaminant. Negative staining electron microscopy
revealed fibril-free preparations of spherical aggregates
with a diameter of 2 to 5 nm (Fig. 1c). Aβ42 globulomers
bind weaker to the fluorescent amyloid-specific dye
thioflavine T (ThT) compared to mature fibrils, as indicated
by the smaller fluorescence intensity signal in the ThT
spectrum (Fig. 1e,f). Moreover, these aggregate species do
not exhibit an increased optical absorption when stained
Fig. 1 Characterization of Aβ42 species. a Coomassie Blue-stained
SDS-PAGE gel reveals predominantly monomeric Aβ42 (MW 4 kDa)
in the disaggregated (monomer) preparation. The preparation does
contain some heterogeneous Aβ peptides that migrate as trimers and
tetramers. Lane 1 Molecular weight marker, lane 2 5 μl of monomer
preparation. b Characterization of the globulomer preparation.
Coomassie Blue-stained SDS-PAGE gel reveals predominantly olig-
omeric Aβ42 (MW 50 kDa). Lane 1 Molecular weight marker, lane 2
after preparation (10 μl), lane 3 after concentration (0.5 μl), lane 4
after concentration and dialysis (0.5 μl), and lane 5 flow through
(10 μl). c, d Electron micrographs of negatively stained Aβ42
globulomers (c) and fibrils (d) reveal spherical aggregates or mature
amyloid fibrils, respectively. e–h ThT fluorescence emission and
Congo Red absorption in the presence (black line) and absence (gray
line) of globulomers (e, g) and fibrils (f, h). i, j ATR-FTIR spectra of
Aβ42 globulomers (i) and fibrils (j). FTIR spectra were normalized to
show equal intensity at the amide I′ maximum. The arrowhead points
at the peak at 1,693 cm −1, characteristic of oligomeric aggregates
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with Congo Red (Fig. 1g). The FTIR spectrum of the Aβ42
globulomers provides further information on their second-
ary structure (Fig. 1i). The maximum of their amide I′ band
is at 1,628 cm−1 and, therefore, within the range that is
typically observed for β-sheet-rich amyloid fibrils [28].
However, the FTIR spectrum of the globulomers shows a
clearly resolvable peak at 1,693 cm−1, which has also been
observed for Aβ40 oligomeric aggregate species and might
indicate antiparallel β-sheet structure [29]. For the glob-
ulomers, the contribution of the main peak at 1,628 cm−1 to
the amide I′ band is smaller than for Aβ42 fibrils,
suggesting that they contain less β-sheet structure.
Natural human Aβ oligomers are formed soon after
generation of the peptide within specific intracellular
vesicles and are subsequently secreted from the cell [30].
Previous studies have shown that these Aβ42 globulomers,
as they have been also termed, are a persistent structural
entity formed independently of the fibrillar aggregation
pathway [24]. These preparations are a potent antigen in
mice and rabbits eliciting the generation of Aβ42 glob-
ulomer-specific antibodies that do not cross-react with the
full-length amyloid precursor protein APP, Aβ40, and
Aβ42 monomers or Aβ fibrils. Furthermore, Aβ42
globulomers have been shown to bind specifically to
Fig. 2 Brain region-specific decrease of membrane potential after a
secondary insult with either oligomeric or fibrillar, but not disaggre-
gated (mainly monomeric), Aβ. Different preparations of Aβ42 were
given to P301L tau transgenic and WT control brain cells and MMP
determined using the fluorescent dye rhodamine 123. a Disaggregated
Aβ42 added at the concentrations indicated for 4 h did not reveal
differences in membrane potential between cortical brain cells of
P301L transgenic and control cells. b Fibrillar preparations of Aβ42
caused a reduced membrane potential at 50 nmol/l for P301L tau and
WT cells (*p<0.05 vs. untreated corresponding control cells). P301L
tau showed a significantly reduced MMP at a concentration of
50 nmol/l Aβ42 compared to WT control mice (#p<0.05) as shown
previously. Two-way ANOVA revealed a significant difference
between both groups (p<0.05). c Oligomeric (globulomeric) prepara-
tions of Aβ42 caused a reduced membrane potential at 50 and
100 nmol/l for WT cells and at 100 nmol/l for P301L tau cells (*p<
0.05 vs. corresponding untreated control cells). P301L tau showed a
significantly reduced MMP at a concentration of 50 nmol/l oligomeric
Aβ42 compared to WT control mice (##p<0.01). Two-way ANOVA
revealed a significant difference between both groups (p<0.05). d
Different from the cortical preparations, cerebellar preparations
obtained from P301L mice are resistant to the effects of all forms of
Aβ42. a–d Values represent means ± SE from n=5–6 animals per
group. All experiments were performed in duplicates
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dendritic processes of neurons but not glia in primary
hippocampal cultures and to completely block long-term
potentiation (LTP) in rat hippocampal slices [30].
Fibrillar Aβ42 was obtained by resuspension of Aβ42 in
TBS and an incubation at 37°C for 24 h as described [16,
25]. Negative staining electron microscopy clearly shows
mature, twisted Aβ42 fibrils with a width of 6 to 12 nm
(Fig. 1d). Aβ42 fibrils show amyloid-typical tinctorial
properties upon binding to ThT and CR (Fig. 1f,h). The
fluorescence intensity of ThT at 482 nm and the CR
absorption increase substantially in the presence of Aβ42
fibrils. Moreover, the maximum of the CR absorption is
shifted from 497 to 513 nm, as typically observed for
amyloid fibrils [29]. The amide I′ band of the fibrils also
has its maximum at 1,628 cm−1 and suggests the presence
of an amyloid-like extended β-sheet structure in Aβ42
fibrils (Fig. 1j). Within the limits of detection, this
preparation was free of oligomers (data not shown).
Both oligomeric and fibrillar Aβ42 cause a decreased
membrane potential in P301L tau cortical preparations
We dissected the cerebellum and two cerebral brain
hemispheres from 6 P301L transgenic and six non-
transgenic control WT littermates at 13–15 months of
age. The cerebellum and one cerebral hemisphere were
triturated separately to obtain cellular preparations to
determine the mitochondrial membrane potential. The
second cerebral hemisphere was used to prepare isolated
mitochondria to determine the rate of mitochondrial
respiration. Brain cells and isolated mitochondria from
the same animals were treated in parallel with the different
Aβ42 preparations.
Basal MMP of cortical brain cells was already reduced
in 13–15-month-old P301L tau compared to WT mice (+p<
0.05; Fig. 2a). Treatment of cortical preparations with
monomeric Aβ42 at a concentration ranging from 0 to
100 nmol/l had no effect on the MMP when P301L tau
preparations were compared with non-transgenic WT
littermate controls (Fig. 2a). In contrast, 50 nmol/l of
fibrillar Aβ42 induced a marked impairment for both the
wild-type and P301L neuronal preparations (Fig. 2b).
Consistent with our previous findings [12], the Aβ42 insult
resulted in a higher reduction in MMP in P301L tau
mitochondria compared to WT (#p≤0.05; Fig. 2b). When
we tested oligomeric preparations, these had a marked
effect on the MMP. WT preparations showed a reduced
MMP with 50 and 100 nmol/l of oligomeric Aβ42. Cortical
preparations from P301L mice showed an even more
pronounced reduction of the MMP at 100 nmol/l (Fig. 2c).
Again, P301L mitochondria showed a significantly reduced
MMP compared to that of WT mitochondria after treatment
with 100 nmol/l of oligomeric Aβ42 (##p<0.01; Fig. 2b).
We conclude from this that cortical preparations of both
WT and P301L tau transgenic mice are susceptible to Aβ42
preparations, be they oligomeric or fibrillar in nature.
Importantly, when we looked at cerebellar preparations,
they were resistant to all three types of Aβ42 preparations
in as much as they showed no impairment of the MMP
(Fig. 2d). This finding underscores the concept of selective
vulnerability in neurodegeneration. For example, for the
Aβ-associated pathology in AD, five phases have been
defined, with only the final fifth phase being characterized
by Aβ deposition in the cerebellum [31, 32]. Similarly,
NFTs are found in the cerebellum only in the final stages of
AD, and in FTD, they are also not frequently encountered
[33]. The mechanisms underlying selective vulnerability in
AD and FTD are largely unknown, and several hypotheses
have been put forward. Interestingly, one of the factors
determining which cells die first when different types of
cells are exposed to the same stress may be variations in
mitochondrial composition [34].
Reduced state 3 respiration, respiratory control ratio,
and uncoupled respiration in P301L tau mice
We have previously shown a significantly reduced state 3,
but not state 4, respiration in aged (24-month-old) P301L
tau transgenic compared to age-matched WT mice; this led
to a markedly reduced respiratory control ratio [19].
In the present study, we restricted our analysis to the
effects of oligomeric and fibrillar Aβ, determining state 3
and 4 respiration, the respiratory control ratio, and
uncoupled respiration. The addition of malate and gluta-
mate to coupled brain mitochondria, which fuel the
mitochondrial NADH-generating system, allowed the anal-
ysis of the complex I-dependent respiration (Fig. 3a,b).
State 3 respiration measures the capacity of mitochondria to
metabolize oxygen and the selected substrate in the
presence of a limited quantity of ADP, which is a substrate
for adenosine triphosphate (ATP) synthase (complex V).
State 4 respiration measures respiration when all ADP is
exhausted and is associated with proton leakage across the
inner mitochondrial membrane. Therefore, it represents a
“basal-coupled” rate of respiration. We found that whereas
state 4 respiration remained unchanged with NADH-
generating substrates in P301L tau mice and WT controls
(Figs. 3b and 4a), a significantly reduced state 3 respiration
could be observed in cortical mitochondria of 13–15-month-old
P301L tau mice treated with Aβ42 (Figs. 3b and 4b).
Consistent with our MMP findings, WT mitochondria
exhibited a reduced sensitivity to Aβ42 insults compared
to P301L mitochondria (two-way ANOVA p<0.05). State 3
respiration was significantly reduced after treatment with
oligomeric Aβ42. A similar trend was also seen after
exposure to Aβ42 fibrils. We have previously shown that
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state 3 respiration is reduced in cortical P301L tau
mitochondria compared to WT controls reflecting reduced
complex I activity [19]. Thus, our data indicate that the
effect exerted by the presence of the P301L tau transgene
on state 3 respiration is exacerbated by Aβ42. The
respiratory control ratio is the ratio of state 3 to state 4
respiration, providing a measure for the efficiency of
coupling of the mitochondrial respiratory chain. The
respiratory control ratio is reduced in P301L tau mice
treated with either oligomeric or fibrillar Aβ42 indicating
that the relative efficiency of metabolic coupling of the
electron chain complexes is impaired by both types of
Aβ42 preparations (Fig. 4c).
We found in addition, after uncoupling with FCCP, that
the respiratory rate in the absence of a proton gradient, i.e.,
the ‘uncoupled respiration’, was significantly diminished in
13–15-month-old P301L tau mice after incubation with
either oligomeric or fibrillar preparations of Aβ42 (Figs. 3b
and 4d) indicating a reduced maximum capacity of the
electron transport chain. After complete inhibition of
complex I with rotenone, succinate was added as a substrate
for complex II. When the succinate-dependent respiration
was normalized to the uncoupled complex I-dependent
respiration in the respective experiments, there was no
significant difference between treated and untreated P301L
tau transgenic mitochondria (Fig. 3b). This indicates that
Fig. 3 Respiration of mitochondria isolated from cortical brain cells
of P301L tau mice upon exposure to different Aβ preparations using
an oxygen electrode. a Representative diagram of measurement of
oxygen (O2) consumption in mitochondria from a 15-month-old
P301L tau mouse demonstrating a decrease in the total O2
concentration with time. b Isolated mitochondria from 13- to 15-
month-old mice were exposed to different preparations of Aβ. Then,
mitochondria were added to the chamber and oxygen (O2) flux and
consumption by mitochondria (mito) was measured after adding
different agents (marked by arrows): malate/glutamate (mal/glu; state
4), ADP (state 3), FCCP, rotenone (rot), succinate (suc), and KCN.
State 4 was measured after adding malate/glutamate. Then, ADP was
added to measure state 3 respiration. After determining coupled
respiration, FCCP was added and respiration was measured in the
absence of a proton gradient. To inhibit complex I activity, rotenone
was added. Then, respiration was measured after adding succinate.
Finally, complex IV activity and O2 consumption was inhibited by
treatment with KCN. Two-way ANOVA reveals a reduced state 3 and
uncoupled respiration in the presence of either fibrillar or oligomeric
Aβ42 (p<0.05) Values represent means ± SE from n=5–6 animals per
group. All experiments were performed in duplicates
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neither complex II nor complex III and IV are decisively
impaired by Aβ42. In accordance with the respiratory
control ratio, we have previously shown that ATP levels of
cerebral cells were unchanged in 12-month-old P301L tau
transgenic mice, but significantly reduced with aging [19].
Previous studies using homogenates of fresh samples of
frontal neocortex from patients with dementia and neuro-
surgical controls suggested partial mitochondrial uncou-
pling in disease as the ratio of oxygen uptake rates in the
presence and absence of ADP was significantly reduced for
the dementia patients compared with controls [35]. These in
vitro results indicate that metabolic changes may be
relevant to the pathogenesis of AD and related dementias
[36].
Together, our results suggest that P301L tau mice exhibit
an initial defect in mitochondrial function with reduced
complex I activity, which is exacerbated by the presence of
either oligomeric or fibrillar Aβ42.
Aging increases the sensitivity of mitochondria
to oligomeric Aβ damage
Mitochondrial respiratory chain failure has been implicated
as a factor in general aging and is likely to have a greater
effect in tissues with a high dependency on energy
generated through oxidative phosphorylation such as the
brain [37]. We have previously shown that aging contrib-
utes to the mitochondrial dysfunction in P301L tau mice
[19]. Furthermore, we had found a 62.3% reduction of
complex V levels in human FTDP-17 brains obtained from
carriers of the P301L mutation, compared to control brains
[19]. The decreased levels of complex V in human P301L
Fig. 4 Reduced state 3 respiration, RCR (respiratory control ratio),
and uncoupled respiration in P301L tau mice. a In mitochondria from
13- to 15-month-old P301L tau transgenic mice, neither fibrillar nor
oligomeric preparations of Aβ42 cause reductions of state 4
respiration. b State 3 respiration, however, was significantly reduced
after treatment with oligomeric Aβ42 in P301L tau cells (+p<0.05).
Two-way ANOVA reveals a significant difference between both
groups with regard to the vulnerability of mitochondria to the
damaging effects of Aβ42 (p<0.05) that is significantly increased in
P301L tau mice. c Reduced respiratory control ratio in 13–15-month-
old P301L tau mitochondria indicating an impaired efficiency of
electron transport in the presence of either oligomeric or fibrillar
Aβ42 (two-way ANOVA p<0.05, post hoc testing revealed +p<0.05
vs. WT). d Reduced uncoupled respiration in 13–15-month-old P301L
tau mitochondria in the presence of either oligomeric or fibrillar Aβ42
(two-way ANOVA p<0.01, post hoc testing revealed +p<0.05 vs.
oligomeric Aβ42-treated WT and ++p<0.01 vs. fibrillar Aβ42-treated
WT). a–d Values represent means ± SE from n=5–6 animals per
group. All experiments were performed in duplicates
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FTDP-17 brains confirmed our proteomics observation
made in the P301L tau transgenic mice and suggested that
the P301L mutant tau pathology causes potentially a
specific mitochondrial dysfunction in humans as well as
in mice [19].
To address the toxicity of Aβ in our experimental
system, we determined the MMP not only with mitochon-
drial preparations obtained from 13–15-month-old, but also
from 21–22-month-old P301L tau transgenic mice follow-
ing incubation with disaggregated (mainly monomeric),
oligomeric, and fibrillar Aβ42 (Fig. 5). Again, treatment of
cortical preparations with disaggregated Aβ42 at a concen-
tration ranging from 0 to 100 nmol/l had no effect on the
MMP when P301L tau preparations were compared with
non-transgenic WT littermate controls (data not shown).
Fibrillar Aβ42 significantly reduced MMP at a concentra-
tion of 50 nmol/l, similar to what we had found in 13–15-
month-old cortical brain cells from P301L and WT mice
(Fig. 5a). In contrast, oligomeric Aβ42 reduced MMP
already at a concentration of 25 nmol/l in cortical WT and
P301L brain cells (Fig. 5b) indicating that not the extent of
mitochondrial damage but the vulnerability to Aβ42
toxicity is enhanced. Notably, cerebellar preparations did
not show an age-related change in the sensitivity to all three
types of Aβ42 preparations in as much as they showed no
impairment of the MMP emphasizing again the concept of
selective vulnerability in AD (data not shown).
Together, aging increased sensitivity of cortical mito-
chondria to Aβ damage. This is in agreement with studies
in APP transgenic mice [25] as well as in primates, where
complex I activity had been shown to be reduced with
aging [38]. Thus, aging potentially intensifies complex I
activity defects in the P301L tau mice.
Discussion
Our findings first of all support the notion of a toxic role of
Aβ in respiration and, together with our previous findings,
antioxidant defense mechanisms [19, 25, 39]. Secondly,
they reveal a role for tau in mitochondrial dysfunction.
Thirdly, our experiments extend our previous findings that
treatment of PC12 cells with extracellular Aβ causes a
significant decrease in mitochondrial membrane potential
[40]. Finally, our results in P301L tau mice indicate the
effects of both fibrillar and oligomeric Aβ on mitochondrial
function of cortical brain cells at very low and physiolog-
ical relevant concentrations within the nanomolar range and
within a very short time frame (incubation time 4 h)
indicating early and chronic alterations of mitochondrial
functions that may impact overall neuronal homeostasis. In
a related study, acute treatment of human cortical neurons
with oligomeric Aβ (5 μM) for only short periods was
shown to be sufficient to activate a mitochondrial apoptotic
death pathway [41].
How does Aβ exert its effect on mitochondria?
Interaction of Aβ with Aβ binding alcohol dehydrogenase
(ABAD), a short-chain alcohol dehydrogenase in the
mitochondrial matrix, has been shown to lead to mitochon-
dria failure, e.g., mitochondrial membrane permeability and
reduction of the activities of enzymes involved in mito-
Fig. 5 Aging increases sensitivity of mitochondria to oligomeric Aβ
damage. a For P301L tau and WT cells from 21- to 22-month-old
mice, fibrillar preparations of Aβ42 cause a reduced membrane
potential at 50 nmol/l (*p<0.05 vs. untreated corresponding control
cells). P301L tau showed a significantly reduced MMP at a
concentration of 50 nmol/l Aβ42 compared to WT control mice
(#p<0.05). Two-way ANOVA revealed a significant difference between
both groups (p<0.05). b Oligomeric (globulomeric) preparations of
Aβ42 caused a reduced membrane potential at 25, 50, and 100 nmol/
l for old WT cells and P301L tau cells from 21- to 22-month-old mice
(*p<0.05, **p<0.01, ***p<0.001 vs. corresponding untreated control
cells). P301L tau showed a significantly reduced MMP at a concentra-
tion of 25 and 100 nmol/l Aβ42 compared to WT control mice (#p<
0.05). Two-way ANOVA revealed a significant difference between both
groups (p<0.01). a, b Values represent means ± SE from n=5–6
animals per group. All experiments were performed in duplicates
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chondrial respiration [42]. ABAD also binds to oligomeric
Aβ42 that has been found in cortical mitochondria of APP
transgenic mice [43]. Protease sensitivity assays suggest
that Aβ gains access to the mitochondrial matrix rather than
simply being adsorbed to the external surface of mitochon-
dria [44]. This may explain how Aβ42 affects mitochon-
drial membrane potential and respiration. In our studies,
however, we did not determine whether there is a direct
interaction between Aβ and mitochondria, nor whether
extracellular Aβ is taken up by the neurons. It is very likely
that within the short time frame of our experiments (i.e.,
4 h) very little Aβ42 is taken up at all. The effects of this
putatively minor fraction cannot be discriminated from that
elicited by the majority of Aβ that is not taken up.
Therefore, our experimental design does not allow drawing
any conclusions concerning the role of intracellular Aβ in
mitochondrial dysfunction. In any case, it is generally not
understood how Aβ exerts its toxicity in other experimental
paradigms, whether it is receptor mediated and if so
whether it requires uptake of Aβ by nerve terminals and
retrograde transport, whether it is dependent on pore
formation and calcium ion influx, or whether it is related
to damage to nerve terminals, by interacting with the lipid
bilayer [45]. It has been hypothesized that oligomeric Aβ,
with its sharp morphology in contrast to monomeric Aβ,
has the ability to permeabilize cellular membranes and lipid
bilayers thereby entering organelles, such as the mitochon-
dria [46, 47]. Of note, early reports about the action of
aggregated Aβ on membranes implicate increased mem-
brane permeability elicited by fibrils [48, 49]. These
mechanisms might explain why aggregated Aβ prepara-
tions elicit effects on mitochondrial function, but not
disaggregated Aβ.
The differences we found between the effects of fibrillar
and oligomeric Aβ are subtle. In a related study, their
effects have been dissected from monomers. Cell medium
containing oligomers and abundant Aβ monomers, but not
amyloid fibrils, were microinjected into rat brain and shown
to markedly inhibit hippocampal long-term potentiation
[30]. Immunodepletion from the medium of all Aβ species
completely abrogated this effect. Pretreatment of the
medium with insulin-degrading enzyme, which degrades
Aβ monomers but not oligomers, did not prevent the
inhibition of LTP, indicating a role for Aβ oligomers. These
were shown to disrupt synaptic plasticity in vivo at
concentrations found in human brain and cerebrospinal
fluid, in the absence of monomeric or fibrillar amyloid.
When cells were treated with γ-secretase inhibitors at doses
which prevented oligomer formation but allowed apprecia-
ble monomer production, this no longer disrupted LTP,
indicating that synaptotoxic Aβ oligomers can be targeted
therapeutically [30, 50]. In Neuro-2A cells, oligomers were
shown to induce a tenfold greater increase in neurotoxicity
as compared to fibrils [51]. However, whereas LTP seems
to be inhibited by oligomeric Aβ only and not by fibrillar
Aβ, in a different experimental paradigm, as in our study,
the two species seem to have both toxic, yet diverse effects
[52]. Using rat astrocyte cultures, oligomeric Aβ42 was
shown to induce initial high levels of the pro-inflammatory
molecule IL-1β that decreased over time, whereas fibrillar
Aβ caused increased levels over time [52]. Oligomeric, but
not fibrillar Aβ, induced high levels of iNOS, NO, and
TNFα, suggesting that oligomers induce a profound, early
inflammatory response, whereas fibrillar Aβ shows less
increases of pro-inflammatory molecules, consistent with a
more chronic form of inflammation [52]. Similarly, in our
experimental paradigm, we found toxic effects of both
fibrillar and oligomeric Aβ, but those of oligomeric Aβ
were more pronounced.
The presence of the pathogenic P301L mutation of tau
severely increased the susceptibility of mitochondria to Aβ
preparations. How tau accumulation is mediating these
changes is unclear. Overexpression of wild-type tau in cell
culture has been shown to impair plus-end-directed axonal
transport resulting in a reduction of mitochondria [53].
However, this is unlikely the case for P301L tau mice, as
mitochondrial neuritic numbers counted proximal or distal
to the cell body, did not vary significantly compared to
numbers in WT mice, [19]. Also, the total amount of
mitochondria has been shown to be unaltered in the
transgenic mice [19]. This is consistent with the finding
of similar numbers of mitochondria between NFT and non-
NFT-bearing cells in AD [54]. It is likely that tau
accumulation has direct effects on the mitochondria as the
accumulation of increasingly insoluble ATP synthase α-
chain together with NFTs has been shown in AD brains
while detergent-soluble levels were reduced [55].
The synergistic effects of Aβ42 on mitochondria isolated
from P301L tau transgenic mice may seem subtle,
irrespective of whether they are incubated with fibrillar or
oligomeric Aβ42, but these effects are of in vivo relevance
as AD is a chronic and slowly progressive disease, with
time spans of up to several decades between Aβ and tau
aggregation and the onset of clinical symptoms.
In conclusion, we found that both fibrillar and oligo-
meric Aβ42 preparations impaired mitochondrial mem-
brane potential and respiration. Furthermore, we revealed
the synergistic effects of Aβ42 and P301L tau (see also:
[56]). However, as aged cortical brain mitochondria showed
an increased sensitivity to oligomeric compared to fibrillar
Aβ, this suggests that oligomeric Aβ may be particularly
toxic. Although it is likely that oligomeric Aβ represents
the primary toxic insult, further experiments are needed to
substantiate this notion. Thus, there is increasing evidence
for different modes of toxic actions of Aβ suggesting that
in the development of treatment strategies, targeting either
J Mol Med (2008) 86:1255–1267 1265
oligomeric or fibrillar Aβ may not be sufficient, but the
best approach is likely one that either prevents formation of
excess Aβ altogether or assists in its rapid clearance.
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